• Thumbnail

    PharmaTimes - January/February

    When thinking about the future of pharma these days, we often find ourselves looking not at the big-name companies, but at the smaller firms at the cutting-edge of the industry. (It’s not just by chance that the industry has been dominated by M&A for the last couple of years.)

  • Beyond 'beyond the pill'

    How pharma companies can take patient-centricity and social responsibility a step further

  • Finding pharma's future

    With pharma changing rapidly and Brexit on the horizon, where is recruitment heading?

News

View all
Thumbnail image for Teva’s subcutaneous asthma drug fails in PhIII

Teva’s subcutaneous asthma drug fails in PhIII

Teva’s quest to expand approval of its respiratory drug Cinquair/Cinqaero with a new mode of delivery has hit a snag, after two late-stage studies failed to hit their targets.

23rd January 2018

Thumbnail image for Rexgenero wins £1.4m grant from Innovate UK

Rexgenero wins £1.4m grant from Innovate UK

London, UK-based Rexgenero has secured with partners £1.4 million in funding for a £1.8 million project from the UK’s innovation agency Innovate UK, for an industrial research project on the commercial manufacture of its product REX-001.

23rd January 2018

Thumbnail image for NICE backs Bayer’s Eylea, Novartis’ Lucentis for sight condition

NICE backs Bayer’s Eylea, Novartis’ Lucentis for sight condition

Cost regulators for NHS-funded therapies in England and Wales have issued updated guidelines for the treatment of wet AMD, which continue to back use of both Bayer’s Eylea and Novartis’ Lucentis, but the GMC says doctors should not fear prescribing Roche's Avastin off-label if they believe it is clinically appropriate and in the patient's best interest.

23rd January 2018

Web Exclusives

View all
Thumbnail image for What's in a name?

What's in a name?

Is the FDA's plan to give all biologics unique non-proprietary names unnecessary?

Thumbnail image for Rare opportunity

Rare opportunity

Inside the world of rare diseases with Joe Wiley, CEO of Amryt Pharma

Thumbnail image for Loud and clear

Loud and clear

We asked the winning companies from the 2017 Communications Team of the Year competition what pharma’s comms priorities should be

Thought Leadership

View all
Thumbnail image for Making digital engagement truly patient-centric

Making digital engagement truly patient-centric

Digitally-augmented multi-channel engagement has proved to be a useful approach for working with patients. However, it is easy for  developers to default to a patient-facing website or an app that looks good and sounds impressive, but in practice doesn’t supply what patients want and need

Thumbnail image for PharmaMar, an innovative oncology company

PharmaMar, an innovative oncology company

PharmaMar is one of the few biopharmaceutical companies to have a product on the market, another awaiting commercialisation and various more at different stages of clinical development

Thumbnail image for Delivering true patient centric communications

Delivering true patient centric communications

The model that sees information flow linearly, from pharmaceutical companies, to healthcare professionals, or patient groups and patients, is outmoded and doesn’t work well for any of the parties involved.

Webinars

View all

Designing Pharma organisations for success

Across all industries, people are changing the ways they engage with products, services, and brands. View more...

Wednesday, 28 September 2016 - 11:00 am
George Underwood
FREE - Listen again now - | VIEW NOW

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download